BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) – BioNTech (22UAy.DE) and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca (AZN.L), and Daiichi Sankyo (4568.T).

COVID-19 vaccine maker BioNTech, which is renewing its focus on its traditional roots in oncology, said in a joint statement with China’s Duality that their drug would be tested on women with a certain type of advanced breast cancer with low levels of a cell surface receptor known as HER2.